195 related articles for article (PubMed ID: 33373871)
41. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
42. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
Kuehn T; Bauerfeind I; Fehm T; Fleige B; Hausschild M; Helms G; Lebeau A; Liedtke C; von Minckwitz G; Nekljudova V; Schmatloch S; Schrenk P; Staebler A; Untch M
Lancet Oncol; 2013 Jun; 14(7):609-18. PubMed ID: 23683750
[TBL] [Abstract][Full Text] [Related]
43. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.
Joly F; Espié M; Marty M; Héron JF; Henry-Amar M
Br J Cancer; 2000 Sep; 83(5):577-82. PubMed ID: 10944595
[TBL] [Abstract][Full Text] [Related]
44. Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer - Preliminary Results From the MENOCOR Study.
Passildas J; Collard O; Savoye AM; Dohou J; Ginzac A; Thivat E; Durando X; Kwiatkowski F; Penault-Llorca F; Abrial C; Mouret-Reynier MA
Clin Breast Cancer; 2019 Feb; 19(1):e74-e84. PubMed ID: 30448088
[TBL] [Abstract][Full Text] [Related]
45. Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan.
Ou HT; Chung WP; Su PF; Lin TH; Lin JY; Wen YC; Fang WT
Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13069. PubMed ID: 31066140
[TBL] [Abstract][Full Text] [Related]
46. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
[TBL] [Abstract][Full Text] [Related]
47. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
Osoba D; Zee B; Pater J; Warr D; Kaizer L; Latreille J
Qual Life Res; 1994 Oct; 3(5):353-64. PubMed ID: 7841968
[TBL] [Abstract][Full Text] [Related]
48. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.
Adjogatse D; Thanopoulou E; Okines A; Thillai K; Tasker F; Johnston SR; Harper-Wynne C; Torrisi E; Ring A
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):692-6. PubMed ID: 24909701
[TBL] [Abstract][Full Text] [Related]
49. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
50. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.
Laquente B; Macarulla T; Bugés C; Martín M; García C; Pericay C; Merino S; Visa L; Martín T; Pedraza M; Carnero B; Guardeño R; Verdaguer H; Mut A; Vilanova D; García A
BMC Palliat Care; 2020 Jul; 19(1):103. PubMed ID: 32650765
[TBL] [Abstract][Full Text] [Related]
51. Correlations between state anxiety and quality of life in metastatic breast cancer patients.
Dragomir BI; Fodoreanu L
Rev Med Chir Soc Med Nat Iasi; 2013; 117(3):610-5. PubMed ID: 24502024
[TBL] [Abstract][Full Text] [Related]
52. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
53. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
Schwentner L; Harbeck N; Singer S; Eichler M; Rack B; Forstbauer H; Wischnik A; Scholz C; Huober J; Friedl TW; Weissenbacher T; Härtl K; Kiechle M; Janni W; Fink V
Breast; 2016 Jun; 27():69-77. PubMed ID: 27054751
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.
Chen J; Yao Q; Li D; Zhang J; Wang T; Yu M; Zhou X; Huan Y; Wang J; Wang L
BMC Cancer; 2013 May; 13():248. PubMed ID: 23693018
[TBL] [Abstract][Full Text] [Related]
55. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
BMC Cancer; 2022 Dec; 22(1):1343. PubMed ID: 36550413
[TBL] [Abstract][Full Text] [Related]
56. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
Möbus V; Lück HJ; Ladda E; Klare P; Schmidt M; Schneeweiss A; Grischke EM; Wachsmann G; Forstbauer H; Untch M; Marmé F; Blohmer JU; Jackisch C; Huober J; Stickeler E; Reinisch M; Link T; Sinn BV; Janni W; Denkert C; Furlanetto J; Engels K; Solbach C; Schmatloch S; Rey J; Burchardi N; Loibl S;
Eur J Cancer; 2021 Oct; 156():138-148. PubMed ID: 34450552
[TBL] [Abstract][Full Text] [Related]
57. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
[TBL] [Abstract][Full Text] [Related]
58. Health-related quality of life and its predictors among patients with breast cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
Sibhat SG; Fenta TG; Sander B; Gebretekle GB
Health Qual Life Outcomes; 2019 Nov; 17(1):165. PubMed ID: 31690327
[TBL] [Abstract][Full Text] [Related]
59. Health-Related Quality of Life among Women Breast Cancer Patients in Eastern China.
Chen Q; Li S; Wang M; Liu L; Chen G
Biomed Res Int; 2018; 2018():1452635. PubMed ID: 30065931
[TBL] [Abstract][Full Text] [Related]
60. Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life.
Wyld L; Reed MWR; Morgan J; Collins K; Ward S; Holmes GR; Bradburn M; Walters S; Burton M; Herbert E; Lifford K; Edwards A; Ring A; Robinson T; Martin C; Chater T; Pemberton K; Shrestha A; Brennan A; Cheung KL; Todd A; Audisio R; Wright J; Simcock R; Green T; Revell D; Gath J; Horgan K; Holcombe C; Winter M; Naik J; Parmeshwar R; Patnick J; Gosney M; Hatton M; Thomson AM
Eur J Cancer; 2021 Jan; 142():48-62. PubMed ID: 33220653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
